خط مشی دسترسیدرباره ما
ثبت نامثبت نام
راهنماراهنما
فارسی
ورودورود
صفحه اصلیصفحه اصلی
جستجوی مدارک
تمام متن
منابع دیجیتالی
رکورد قبلیرکورد بعدی
center : Isfahan University of Medical Sciences
Document Type : Latin Dissertation
Language of Document : English
Record Number : 103462
Doc. No : T15057
Call number : ‭WK,820,D712e,2014‬
Main Entry : Dormiani Tabatabai, Mehrnaz
Title & Author : The effect of pioglitazone on circulating interleukin-10 and tumour necrosis factor-alpha levels in patient with metabolic syndrome: a randomized, double-blind controlled trial/مهرناز درمیانی طباطبایی
College : Schools, Medical
Date : , 2014
Degree : Cardiology, Speciality
Page No : [15] p.: tab.
Note : This thesis is a research project with project ID: 393231
Abstract : Background: This study aimed to evaluate the effect of pioglitazone as an insulin sensitizer on circulating interleukin-10 (IL-10) as an anti-inflammatory factor and tumour necrosis factor-alpha (TNF-alfa) as main pre-inflammatory factor in nondiabetic metabolic syndrome (MetS) patients in Caucasians race of Middle East area in Iran. Methods: We conducted a randomized double-blind controlled study of 68 nondiabetic patients with MetS. Patients were randomly divided into two groups including intervention group received pioglitazone 30 mg daily for 24 weeks and the control group received placebo pills for the same duration. Circulating levels of TNF-alfa and IL-10 were assessed as a primary goal. Lipid profile, liver enzymes, blood pressure, waist circumference and body mass index (BMI) also were measured.Results: Lipid profile had non-significant changes after treatment by pioglitazone, but BMI was increased significantly (P = 0.002). Blood pressure and waist circumference had significant decrease in both groups (P < 0.050). Aspartate transaminase and alanine transaminase were decreased significantly in pioglitazone group (P = 0.002). TNF-alfa decreased non-significantly in both groups (P > 0.050). IL-10 increased in intervention group non-significantly (P = 0.971); while in placebo group decreased to a little extent (P = 0.401). C-reactive protein was also decreased insignificant after receive pioglitazone (P = 0.333). There was no significant difference in all variables between the two groups (P > 0.050). Conclusion: This study indicates that pioglitazone has no positive effect on improving inflammatory status in the non-diabetes patients with MetS.
Descriptor : 1.Metabolic Syndrome X.- Descriptors: Metabolic Syndrome X
: pioglitazone
: Interleukins
Added Entry : Sadeghi, Masoumeh, Supervisor
: Pourmoghadas, Ali, Supervisor
Translated Title Supplied by Cataloguer : بررسی اثر پیوگلیتازون بر سطح سرمی اینترلوکین‭ ۱۰ ‬و ‭TNFa‬ در بیماران مبتلا به سندرم متابولیک
عنوان :
نام فایل :
نوع عام محتوا :
نوع ماده :
فرمت :
سایز :
عرض :
طول :
The effect of pioglitazone on circulating interleukin-10 ...
dormiani tabatabai mehrnaza.pdf
پایان نامه لاتین
متن
application/force-download
105 KB
85
85